Analysts expect Recursion Pharmaceuticals to report a Q2 2026 consensus revenue of $10.97 million and an EPS loss of $0.25, with the stock currently trading near $3.00 against an average analyst price target of $8.00. The primary focus for investors this quarter is the company's progress in its AI-driven drug discovery pipeline, specifically updates on the REC-1245 clinical trials and the strategic integration of the recently acquired Exscientia.
Recursion continues to navigate a pre-revenue biotech environment characterized by high R&D spending and a heavy reliance on collaboration milestones from partners like Roche and NVIDIA. While the company beat EPS estimates in the previous quarter, revenue significantly lagged expectations, making the stability of its cash runway and clinical momentum critical themes for this report.